The Road Map for the Future

With the return to in-person trade shows comes the excitement of witnessing technological advances firsthand. Aurora Multimedia, a company dedicated to changing the topology of AV, participates in many of these events, like the Integrated Systems Europe show in Spain on May 10–13. In this episode of Cutting Through, host Tyler Kern spoke with Aurora’s CEO, Paul Harris, about their new products rolling out this year.

One such product is a new AV over 1G IP solution — a true industry first — that employs a soft version of the technology inside the core engine with no moving parts and no fan. Harris explained, “The most exciting is the VPX. For those that know our products… they know of the IPX, which has our 1G and our 10G, but now VPX puts it right in the middle, but it’s a high-performing product. It is a 4K60 4:4:4 over AV over IP product that uses only eight watts of power.”

Harris also spoke briefly about the DTX and RXT series before disclosing a few teasers of what’s still to come in 2022, like the DIDO series they’re bringing back. Developed almost 20 years ago as the first real-time image rotation engine on the market, DIDO lived for about 12 years before dying because the tech became too difficult to support. To not spoil the fun with all the details, Harris promised “it will be even more amazing than the original generation.”

Another exciting rollout is the ASP 42, but he only divulged two features for that one, including capture capabilities and the ability to plug the devices directly into the computer.

Visit Aurora to learn more and keep apprised of the company’s future trade show events.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More